Selegiline remarkably improved stage 5 treatment-resistant major depressive disorder: a case report

We report a case in which selegiline, an irreversible monoamine oxidase B (MAO-B) inhibitor, greatly improved depressive symptoms in an adult with stage 5 treatment-resistant major depressive disorder. Four antidepressants and four augmentation therapies had previously been ineffective or intolerabl...

Descripción completa

Detalles Bibliográficos
Autores principales: Kitaichi, Yuji, Inoue, Takeshi, Mitsui, Nobuyuki, Nakagawa, Shin, Kameyama, Rie, Hayashishita, Yoshiyuki, Shiga, Tohru, Kusumi, Ichiro, Koyama, Tsukasa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3804584/
https://www.ncbi.nlm.nih.gov/pubmed/24204150
http://dx.doi.org/10.2147/NDT.S49261

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3804584/
https://www.ncbi.nlm.nih.gov/pubmed/24204150
http://dx.doi.org/10.2147/NDT.S49261

Ejemplares similares